Healthcare

Johnson & Johnson seeks first EU approval of nipocalimab to treat a broad population of patients living with antibody-positive generalised myasthenia gravis

Marks first EMA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and...

error: Content is protected !!